You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Iptacopan for treating paroxysmal nocturnal haemoglobinuria

  • Technology appraisal guidance
  • Reference number: TA1000
  • Published:  04 September 2024
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Expected publication
  2. Declaration of interests
  3. Final draft guidance
  4. Invitation to participate
  5. Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176

History

Documents created during the development process.

Expected publication

  • Equality impact assessment (guidance development) (PDF 158 KB)

    Published:
    04 September 2024

Declaration of interests

  • Register of interests (PDF 229 KB)

    Published:
    08 November 2024

Final draft guidance

  • Final draft guidance

  • Final draft guidance (PDF 239 KB)

    Published:
    17 May 2024
  • Committee papers (PDF 9.05 MB)

    Published:
    17 May 2024
  • Public committee slides (PDF 1.33 MB)

    Published:
    17 May 2024
  • Equality impact assessment (PDF 158 KB)

    Published:
    17 May 2024

Invitation to participate

  • Final scope (PDF 173 KB)

    Published:
    22 August 2023
  • Final stakeholder list (PDF 152 KB)

    Published:
    22 August 2023
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 348 KB)

    Published:
    22 August 2023
  • Equality Impact Assessment (Guidance development) (PDF 127 KB)

    Published:
    22 August 2023

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6176

  • Draft matrix post referral (PDF 152 KB)

    Published:
    24 May 2023
  • Draft scope post referral (PDF 180 KB)

    Published:
    24 May 2023
Back to top